Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.

Srinivasan S, Stephens C, Wilson E, Panchadsaram J, DeVoss K, Koistinen H, Stenman UH, Brooks MN; Practical Consortium, Buckle AM, Klein RJ, Lilja H, Clements J, Batra J.

Clin Chem. 2018 Dec 11. pii: clinchem.2018.295790. doi: 10.1373/clinchem.2018.295790. [Epub ahead of print]

PMID:
30538125
2.

Perspective on Prostate Cancer Screening.

Carlsson SV, Lilja H.

Clin Chem. 2018 Nov 20. pii: clinchem.2018.293514. doi: 10.1373/clinchem.2018.293514. [Epub ahead of print] No abstract available.

PMID:
30459166
4.

Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ.

Eur Urol. 2018 Dec;74(6):710-719. doi: 10.1016/j.eururo.2018.06.021. Epub 2018 Jul 7.

PMID:
30289108
5.

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Thorek DL, Ku AT, Mitsiades N, Veach D, Watson PA, Metha D, Strand SE, Sharma SK, Lewis JS, Abou DS, Lilja HG, Larson SM, McDevitt MR, Ulmert D.

Clin Cancer Res. 2018 Sep 25. doi: 10.1158/1078-0432.CCR-18-1521. [Epub ahead of print]

PMID:
30254080
6.

Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.

Frånlund M, Arnsrud Godtman R, Carlsson SV, Lilja H, Månsson M, Stranne J, Hugosson J.

Scand J Urol. 2018 Sep 21:1-7. doi: 10.1080/21681805.2018.1508166. [Epub ahead of print]

PMID:
30241447
7.

Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.

Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA, Wilson KM.

Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30627-4. doi: 10.1016/j.eururo.2018.08.032. [Epub ahead of print]

PMID:
30237027
8.

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T.

Br J Cancer. 2018 Aug;119(3):347-356. doi: 10.1038/s41416-018-0172-0. Epub 2018 Jul 10.

PMID:
29988112
9.

Acoustic Enrichment of Extracellular Vesicles from Biological Fluids.

Ku A, Lim HC, Evander M, Lilja H, Laurell T, Scheding S, Ceder Y.

Anal Chem. 2018 Jul 3;90(13):8011-8019. doi: 10.1021/acs.analchem.8b00914. Epub 2018 Jun 11.

PMID:
29806448
10.

Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.

Vickers A, Nordström T, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2018 Aug;74(2):e35-e36. doi: 10.1016/j.eururo.2018.04.027. Epub 2018 May 3. No abstract available.

PMID:
29731258
11.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D.

Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.

12.

Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Sjoberg DD, Vickers AJ, Assel M, Dahlin A, Poon BY, Ulmert D, Lilja H.

Eur Urol. 2018 Jun;73(6):941-948. doi: 10.1016/j.eururo.2018.02.016. Epub 2018 Mar 5.

PMID:
29519548
13.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

14.

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project.

Assel MJ, Gerdtsson A, Thorek DLJ, Carlsson SV, Malm J, Scardino PT, Vickers A, Lilja H, Ulmert D.

Oncotarget. 2017 Dec 5;9(5):5778-5785. doi: 10.18632/oncotarget.22981. eCollection 2018 Jan 19.

15.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, Mehta D, Murray KS, Lilja H, Ulmert D, Monette S, Scherz A, Coleman JA.

Clin Cancer Res. 2018 May 15;24(10):2408-2416. doi: 10.1158/1078-0432.CCR-17-3474. Epub 2018 Feb 20.

PMID:
29463549
16.

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2018 Jun;199(6):1470-1474. doi: 10.1016/j.juro.2018.01.070. Epub 2018 Jan 31.

PMID:
29366640
17.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

18.

Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis.

Cushing K, Undvall E, Ceder Y, Lilja H, Laurell T.

Anal Chim Acta. 2018 Feb 13;1000:256-264. doi: 10.1016/j.aca.2017.11.064. Epub 2017 Dec 5.

PMID:
29289318
19.

Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.

Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Scand J Urol. 2018 Feb;52(1):27-37. doi: 10.1080/21681805.2017.1411392. Epub 2017 Dec 18.

PMID:
29254399
20.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2017 Nov 11. pii: S2405-4569(17)30258-4. doi: 10.1016/j.euf.2017.11.002. [Epub ahead of print]

PMID:
29137895

Supplemental Content

Loading ...
Support Center